A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure

by | Oct 2, 2026 | Clinical Trials | 0 comments

​ Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: SKB264+SKB118

Sponsors: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Not yet recruiting Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Drug: SKB264+SKB118
Sponsors: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *